🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Nitrofurazone Group 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  2. Nivolumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Biliary Tract Cancer(BTC)

    phase 2 small molecule active

    1 trial

  3. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  4. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  5. OMC and pseudo-SDT

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other completed

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

  7. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  8. OPDIVO 10 mg/mL concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  10. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Shanghai Reinovax Biologics Co.,LTD

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  11. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  12. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  13. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  14. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  15. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  16. Obinutuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  17. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Obinutuzumab Injection [Gazyva]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  19. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  20. Octacalcium phosphate

    The First People's Hospital of Lianyungang

    Tooth Extraction

    phase 2 other completed

    1 trial

  21. Octreotide Acetate

    United Therapeutics Europe Ltd

    Liver Transplantation

    phase 2 small molecule active

    1 trial

  22. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  23. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  24. Olverembatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources